Sclerostin has been identified as an important regulator of bone homeostasis through inhibition of the canonical Wnt-signaling pathway, and it is involved in the pathogenesis of many different skeletal diseases. Many studies have been published in the last few years regarding sclerostin's origin, regulation, and mechanism of action. The ongoing research emphasizes the potential therapeutic implications of sclerostin in many pathological conditions with or without skeletal involvement. Antisclerostin antibodies have recently been approved for the treatment of osteoporosis, and several animal studies and clinical trials are currently under way to evaluate the effectiveness of antisclerostin antibodies in the treatment of other than osteoporosis skeletal disorders and cancer with promising results. Understanding the exact role of sclerostin may lead to new therapeutic approaches for the treatment of skeletal disorders.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836457 | PMC |
| http://dx.doi.org/10.3390/jcm11030806 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Role of sclerostin in mastocytosis bone disease.
Sci Rep
January 2025
Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Staszica Street 11, 20-081, Poland.
Mastocytosis is a heterogeneous group of disorders, characterized by accumulation of clonal mast cells which can infiltrate several organs, most often spine (70%). The pathogenesis of mastocytosis bone disease is poorly understood. The main aim of the study was to investigate whether neoplastic mast cells may be the source of sclerostin and whether there is an association between sclerostin and selected bone remodeling markers with mastocytosis related bone disease.
View Article and Find Full Text PDFSclerostin as a new target of diabetes-induced osteoporosis.
Front Endocrinol (Lausanne)
December 2024
Department of Endocrinology and Metabolism, Want Want Hospital, Changsha, Hunan, China.
Sclerostin, a protein synthesized by bone cells, is a product of the gene. Sclerostin is a potent soluble inhibitor of the WNT signaling pathway, and is known to inhibit bone formation by inhibiting osteocyte differentiation and function. Currently, sclerostin has been the subject of numerous animal experiments and clinical investigations.
View Article and Find Full Text PDFThe DLEU2-miR-15a-16-1 Cluster Is a Determinant of Bone Microarchitecture and Strength in Postmenopausal Women and Mice.
Int J Mol Sci
November 2024
Blood Sciences (Pathology), James Cook University Hospital, Middlesbrough TS4 3BW, UK.
This study explores how select microRNAs (miRNAs) influence bone structure in humans and in transgenic mice. In trabecular bone biopsies from 84 postmenopausal women (healthy, osteopenic, and osteoporotic), we demonstrate that (deleted in lymphocytic leukemia 2)-encoded is strongly positively associated with bone mineral density (BMD) at different skeletal sites. In bone transcriptome analyses, levels correlated positively with the osteocyte characteristic transcripts (encoding sclerostin) and (Matrix Extracellular Phosphoglycoprotein), while the related showed a negative association with BMD and osteoblast markers.
View Article and Find Full Text PDFHealth implications of racial differences in serum growth differentiation factor levels among men with obesity.
Physiol Rep
December 2024
Division of Endocrinology Diabetes and Metabolism at Baylor College of Medicine, Houston, Texas, USA.
Article Synopsis
- The study examined the role of Growth differentiation factor (GDF15) in relation to health markers in obese men of different racial and ethnic backgrounds.
- It involved 193 participants and assessed various health metrics including body composition, hormonal levels, and bone mineral density.
- Findings indicated that GDF15 levels were higher in non-African Americans than in African Americans, and its relations to glucometabolic status and body composition varied by ethnicity, highlighting potential racial differences in health risks.
The Bone-Vascular Axis: A Key Player in Chronic Kidney Disease Associated Vascular Calcification.
Kidney Dis (Basel)
December 2024
Department of Nephrology, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
Background: The bone-vascular axis plays a key role in the pathogenesis of vascular calcification (VC) in patients with chronic kidney disease (CKD). Understanding and managing the role of the bone-vascular axis in CKD-mineral and bone disorder (CKD-MBD) is critical for preventing and treating associated complications, including osteoporosis, arterial calcification, and cardiovascular diseases. This study aimed to comprehensively summarize the role of bone metabolism markers in uremic VC.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!